MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.91
-4.57
-9.63%
After Hours: 43.34 +0.43 +1.00% 16:00 01/21 EST
OPEN
47.50
PREV CLOSE
47.48
HIGH
48.06
LOW
42.86
VOLUME
497.17K
TURNOVER
--
52 WEEK HIGH
61.29
52 WEEK LOW
22.00
MARKET CAP
1.74B
P/E (TTM)
-32.4216
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Zentalis Pharmaceuticals Price Target Announced at $65.00/Share by Wedbush
Dow Jones · 1d ago
DJ Zentalis Pharmaceuticals Initiated at Outperform by Wedbush
Dow Jones · 1d ago
Analyst Actions: Wedbush Starts Zentalis Pharmaceuticals at Outperform With $65 Price Target
MT Newswires · 1d ago
Zentalis initiates multiple early-stage clinical trials for cancer
The clinical-stage biopharma, Zentalis Pharmaceuticals (ZNTL) announces that it has started the patient dosing in two combination trials and one monotherapy clinical trial in the Phase 1 stage as mentioned
Seekingalpha · 01/06 12:38
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
Advancing the development of its oral SERD, WEE1 inhibitor and BCL-2 inhibitor product candidatesNEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on ...
GlobeNewswire · 01/06 12:00
Who Has Been Buying Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Simply Wall St. · 12/23/2020 10:20
Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Raises Price Target to $75
Morgan Stanley maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Overweight and raises the price target from $50 to $75.
Benzinga · 12/16/2020 18:21
Is ZNTL A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on ...
Insider Monkey · 12/13/2020 03:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZNTL. Analyze the recent business situations of Zentalis Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZNTL stock price target is 58.33 with a high estimate of 75.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 32.18M
% Owned: 79.25%
Shares Outstanding: 40.61M
TypeInstitutionsShares
Increased
35
4.02M
New
12
1.32M
Decreased
9
115.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Anthony Sun
Co-Founder/Chief Operating Officer
Kevin Bunker
Chief Financial Officer
Melissa Epperly
Senior Vice President
Peter Huang
Senior Vice President
Ahmed Samatar
Senior Vice President
Dimitris Voliotis
Vice President - Operations
Orna Bornstein
Vice President/General Counsel
Kimberley Overs
Vice President
Meena Rao
Other
Lawrence Cripe
Other
Alexis Pinto
Director
Cam Gallagher
Director
Dave Johnson
Independent Director
Kimberly Blackwell
Independent Director
David Johnson
Independent Director
Karan Takhar
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZNTL
Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.
More

Webull offers kinds of Zentalis Pharmaceuticals Inc stock information, including NASDAQ:ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.